FIGURE 4.

a, b, d, e) Serial images of a 70-year-old female patient with stage III nonsmall cell lung cancer who had completed chemoradiotherapy followed by durvalumab. c, f) The radiotherapy treatment plan with a colour-wash display of regions receiving a radiation dose of 30 Gy or higher. 2 months after commencing durvalumab the patient was diagnosed with a grade 2 radiation pneumonitis based upon diffuse ground-glass changes in the irradiated regions in the right lung. g–i) Subsequently, a diagnosis of coexisting immune checkpoint blockade pneumonitis was made based on the appearance of ground-glass abnormalities in the unirradiated contralateral upper lobe.